NMR for the design of functional mimetics of protein-protein interactions: One key is in the building of bridges

Biochemistry and Cell Biology

Volumn 76, Issue 2-3, 1998, Pages 177-188

  Song, Jianxing ^a   Ni, Feng ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Bridge binding inhibitors; Functional mimetics; NMR; Protein protein interactions; Thrombin

Indexed keywords

HIRUDIN; THROMBIN;

ANTICOAGULATION; BINDING AFFINITY; BINDING SITE; HEMOSTASIS; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW; SITE DIRECTED MUTAGENESIS;

EID: 0032467377     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/o98-046     Document Type: Review

References (67)

1. Anfinsen, C.B. 1973. Principles that govern the folding of protein chains. Science (Washington, D.C.), 181: 223-230.
2. Atassi, M.Z., and Manshouri, T. 1993. Design of peptide enzymes (pepzymes): surface-simulation synthetic peptides that mimic the chymotrypsin and trypsin active sites and exhibit the activity and specificity of the respective enzyme. Proc. Natl. Acad. Sci. U.S.A. 90: 8282-8286.
3. Bajusz, S., Barabas, E., Tolnay, P., Szell, E., and Bagdy, D. 1978. Inhibition of thrombin and trypsin by tripeptide aldehydes. Int. J. Pept. Protein Res. 12: 217-221.
4. Balaram, P., Bothner-By, A.A., and Dadok, J. 1972a. Negative nuclear Overhauser effects as probes of macromolecular structure. J. Am. Chem. Soc. 94: 4015-4017.
5. Balaram, P., Bothner-By, A.A., and Dadok, J. 1972b. Localization of tyrosine at binding of neurophysin II by negative nuclear Overhauser effects. J. Am. Chem. Soc. 94: 4017-4018.
6. Blombäck, B., Blombäck, M., Olsson, P., Svendsen, L., and Aberg, G. 1969. Synthetic peptides with anticoagulant and vasodilating activity. Scand. J. Clin. Lab. Invest. Suppl. 24: 59-64.
7. Blombäck, B., Hessel, B., Hogg, D., and Claesson, G. 1977. Substrate specificity of thrombin on proteins and synthetic subtrates. In Chemistry and biology of thrombin. Edited by R. Lundblad and K.G. Mann. Ann Arbor Science Press, Ann Arbor, Mich. pp. 275-290.
8. Braisted, A., and Wells, J.A. 1996. Minimizing a binding domain from protein A. Proc. Natl. Acad. Sci. U.S.A. 93: 5688-5692.
9. Braun, P.J., Dennis, S., Hofsteenge, J., and Stone, S.R. 1988. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry, 27: 6517-6522.
10. Campbell, A.P., and Sykes, B.D. 1993. The two-dimensional transferred nuclear Overhauser effect: theory and practice. Annu. Rev. Biophys. Biomol. Struct. 22: 99-122.
11. Chang, J.Y. 1983. The functional domain of hirudin, α thrombin-specific inhibitor. FEBS Lett. 164: 307-313.
12. Chang, J.Y. 1989. The hirudin-binding site of human α-thrombin. J. Biol. Chem. 264: 7141-7146.
13. Chang, J.Y., Schlaeppi, J.M., and Stone, S.R. 1990. Antithrombin activity of the hirudin N-terminal core domain residues 1-43. FEBS Lett. 260: 209-212.
14. Clackson, T., and Wells, J.A. 1995. A hot spot of binding energy in a hormone-receptor interface. Science (Washington, D.C.), 267: 383-386.
15. Corey, D.R., and Philips, M.A. 1994. Cyclic peptides as proteases. Proc. Natl. Acad. Sci. U.S.A. 91: 4106-4109.
16. Cunningham, B.C., and Wells, J.A. 1989. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science (Washington, D.C.), 244: 1081-1085.
17. Cunningham, B.C., and Wells, J.A. 1997. Minimized proteins. Curr. Opin. Struct. Biol. 7: 457-462.
18. Davies, D.R., Padian, E.A., and Sheriff, S. 1990. Antibody-antigen complexes. Annu. Rev. Biochem. 59: 439-473.
19. de Vos, A.M., Ultsch, A.A., and Kossiakoff, A.A. 1992. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science (Washington, D.C.), 255: 306-312.
20. DiMaio, J., Gibbs, B., Munn, D., Lefebvre, J., Ni, F., and Konishi, Y 1990. Bifunctional thrombin inhibitors based on the sequence of hirudin. J. Biol. Chem. 265: 21698-21703.
21. DiMaio, J., Ni, F., Gibbs, B., and Konishi, Y. 1991. A new class of potent thrombin inhibitors that incorporate a scissile pseudopeptide bond. FEBS Lett. 287: 47-52.
22. DiMaio, J., Ni, F., and Konishi, Y. 1997. Thrombin inhibitors based on the amino acid sequence of hirudin. Japanese patent No. 2669510.
23. Dodt, J., Muller, H.P., Seemüller, U., and Chang, J.Y. 1984. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett 165: 180-183.
24. Fenton, J.W., II. 1981. Thrombin specificity. Ann. N.Y. Acad. Sci. 370: 468-495.
25. Fenton, J.W., II, Ofosu, F.A., Moon, D.G., and Maraganore, J.M. 1991. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagul. Fibrinolysis, 2: 69-75.
26. Fenton, J.W., II, Ni, F., Witting, I., Brezniak, D.V., Andersen, T.T., and Malik, A.B. 1993. The rational design of thrombin-directed antithrombotics. In The design of synthetic inhibitors of thrombin. Edited by G. Claeson. Plenum Press, New York.
27. Folkers, P.J., Clore, G.M., Driscoll, P.C., Dodt, J., Kohler, S., and Gronenborn, A.M. 1989. Solution structure of recombinant hirudin and the Lys-47-Glu mutant: a nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing study. Biochemistry, 28: 601-617.
28. Hajduk, P.J., Sheppard, G., Nettesheim, D.G., Olejniczak, E.T., Shuker, S.B., Meadows, R.P., Steinman, D.H., Carrera, G.M., Marcott, P.A., Jr., Severin, J., Walter, K., Smith, H., Gubbins, E., Simmer, R., Holzman, T.F., Morgan, D.W., Davidsen, S.K., Summers, J.B., and Fesik, S.W. 1997. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 119: 5816-5827.
29. Haruyama, H., and Wüthrich, K. 1989. Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance. Biochemistry, 28: 4301-4312.
30. Hubbard, R.E. 1997. Can drug be designed? Curr. Opin. Biotechnol. 8: 696-700.
31. Janin, J., and Chothia, C. 1990. The structure of protein-protein recognition sites. J. Biol. Chem. 265: 16027-16030.
32. Jencks, W.P. 1981. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U.S.A. 78: 4046-4050.
33. Kettner, C., and Shaw, E. 1979. D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin Thromb. Res. 14: 969-973.
34. Krishnan, R., Tulinsky, A., Vlasuk, G.P., Pearson, D., Vallar, P., Bergum, P., Brunck, T.K., and Ripka, W.C. 1996. Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an α-keto-amide transition-state mimetic. Protein Sci. 5: 422-433.
35. Laudano, A.P., and Doolittle, R.F. 1980. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry, 19: 1013-1019.
36. Li, B., Tom, J.Y., Oare, D., Yen, R., Fairbrother, W.J., Wells, J.A., and Cunningham, B.C. 1995. Minimization of a polypeptide hormone. Science (Washington, D.C.), 270: 1657-1660.
37. Maraganore, J.M., Bowidon, P., Jablonski, J., Ramacandran, K.L., and Fenton, J.W., II. 1990. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry, 29: 7095-7101.
38. Markwardt, F., Hauptmann, J., Nowak, G., Klessen, C., and Walsmann, P. 1982. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb. Haemostasis, 47: 226-229.
39. 10. Biochemistry, 22: 4170-4174.
40. Ni, F. 1994. Recent developments in transferred NOE methods. Prog. Nucl. Magn. Reson. Spectrosc. 26: 517-606.
41. Ni, F., Lord, S.T., and Scheraga, A. 1988. High-resolution NMR studies of fibrinogen-like peptides in solution: resonance assignments and conformational analysis of residues 1-23 of the Aα chain of human fibrinogen. Biochemistry, 27: 4481-4491.
42. Ni, F., and Scheraga, H.A. 1994. Use of the transferred nuclear Overhauser effect to determine the conformations of ligands bound to protein. Acc. Chem. Res. 27: 257-264.
43. Ni, F., Konishi, Y., Frazier, R.B., Lord, S.T., and Scheraga, H.A. 1989a. High-resolution NMR studies of fibrinogen-like peptides in solution: interaction of thrombin with residues 1-23 of the A α chain of human fibrinogen. Biochemistry, 28: 3082-3094.
44. Ni, F., Konishi, Y., Frazier, R.B., Lord, S.T., and Scheraga, H.A. 1989b. High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the Aα chain of human fibrinogen. Biochemistry, 28: 3094-3105.
45. Ni, F., Konishi, Y., Frazier, R.B., Lord, S.T., and Scheraga, H.A. 1989c. High-resolution NMR studies of fibrinogen-like peptides in solution: structural basis for the bleeding disorder caused by a single mutation of Gly(12) to Val(12) in the Aα chain of human fibrinogen Rouen. Biochemistry, 28: 3094-3105.
46. Ni, F., Konishi, Y., and Scheraga, H.A. 1990. Thrombin-bound conformation of the C-terminal fragments of hirudin determined by transferred nuclear Overhauser effects. Biochemistry, 29: 4479-4489.
47. Ni, F., Ripoll, D.R., Martin, P.D., and Edwards, F.P. 1992a. Solution structure of a platelet receptor peptide bound to bovine a-thrombin. Biochemistry, 31: 11551-11557.
48. Ni, F., Gibson, K.D., and Scheraga, H.A. 1992b. Nuclear magnetic resonance studies of thrombin-fibrinopeptide and thrombin-hirudin complexes. In Thrombin: structure and function. Edited by L.J. Berliner. Plenum Press, New York. pp. 63-85.
49. Ni, F., Ning, Q., Jackson, M.J., and Fenton, J.W., II. 1993. Thrombin exosite for fibrinogen recognition is partially accessible in prothrombin. J. Biol. Chem. 268: 16899-16902.
50. Ni, F., Zhu, Y., and Scheraga, A. 1995. Thrombin-bound structures of designed analogies of human fibrinopeptide A determined by quantitative transferred NOE spectroscopy: a new structural basis for thrombin specificity. J. Mol. Biol. 252: 656-671.
51. Ning, Q., Ripoll, D.R., Szewczuk, Z., Konishi, Y., and Ni, F. 1994. Thrombin-bound conformation of a cyclic anticoagulant peptide using transferred nuclear Overhauser effect (NOE), distance geometry, and NOE simulations. Biopolymers, 34: 1125-1137.
52. Novotny, J., Bruccoleri, R.E., and Saul, F.A. 1989. On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5. Biochemistry, 28: 4735-4749.
53. Olejniczak, E.T., Hajduk, P.J., Maracotte, P.A., Nettesheim, D.G., Meadows, R.P., Edalji, R., Holzman, T.F., and Fesik, S.W. 1997. Stromelysin inhibitors designed from weakly bound fragments: effects of linking and cooperativity. J. Am. Chem. Soc. 119: 5828-5832.
54. Otting, G. 1993. Experimental NMR techniques for studies of protein-ligand interactions. Curr. Opin. Struct. Biol. 3: 760.
55. Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Rottsch, C., and Fenton, J.W., II. 1990. The structure of a complex of recombinant hirudin and human α-thrombin. Science (Washington, D.C.), 249: 277-280.
56. Scheraga, H.A. 1986. Chemical basis of thrombin interactions with fibrinogen. Ann. N.Y. Acad. Sci. 485: 124-133.
57. Shuker, S.B., Hajduk, P.J., Meadows, R.P., and Fesik, S.W. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science (Washington, D.C.), 274: 1531-1534.
58. Stone, S.R., Braun, P.J., and Hofsteenge, J. 1987. Identification of regions of alpha-thrombin involved in its interaction with hirudin. Biochemistry, 26: 4617-4624.
59. Svendsen, L., Blombäck, B., Blombäk, M., and Olsson, P.I. 1972. Substrates for determination of trypsin, thrombin and thrombin-like enzymes. Folia Haematol. (Leipzig), 98: 446-454.
60. Szewczuk, Z., Gibbs, B.F., Yue, S.Y., Purisima, E.O., and Konishi, Y. 1992. Conformational restricted thrombin inhibitors resistant to protelytic digestion. Biochemistry, 31: 9132-9140.
61. Van de Locht, A., Lamba, D., Bauer, M., Huber, R., Friedrick, T., Kroger, B., Hoffken, W., and Bode, W. 1995. Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J. 14: 5149-5157.
62. Wells, J.A., Fairbrother, W.J., Otlewski, J., Laskowski, M., Jr., and Bonier, J. 1994. A reinvestigation of a synthetic peptide (TrPepz) designed to mimic trypsin. Proc. Natl. Acad. Sci. U.S.A. 91: 4110-4114.
63. Wrighton, N.C., Farrell, F.X., Chang, R., Kashyap, A., Barbone, F.P., Mulcahy, L.S., Johnson, D.L., Barrett, R.W., Jolliffe, L.K., and Dower, W.J. 1996. Small peptides as potent mimetics of the protein hormone erythropoietin. Science (Washington, D.C.), 273: 458-463.
64. Yanofsky, S.D., Baldwin, D.N., Butler, J.H., Holden, F.R., Jacobs, J.W., Balasubramanian, P., Chinn, J.P., Cwirla, S.E., Peters-Bhatt, E., Whitehorn, E.A., Tate, E.H., Akeson, A., Bowlin, T.L., Dower, W.J., and Barrett, R.W. 1996. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl. Acad. Sci. U.S.A. 93: 7381-7386.
65. Yue, S.Y., DiMaio, J., Szewczuk, Z., Purisima, E.O., Ni, F., and Konishi, Y. 1992. Characterization of the interactions of a bifunctional inhibitor with α-thrombin by molecular modelling and peptide synthesis. Protein Eng. 5: 77-85.
66. Zdanov, A., Wum, S., DiMaio, J., Konishi, Y., Li, Y., Wu, X., Edwards, B.F.P., Matin, P.D., and Cygler, M. 1993. Crystal structure of the complex of human a-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6. Proteins Struct. Funct. Genet. 17: 252-265.
67. Zheng, Z., Ashton, R.W., Ni, F., and Scheraga, H.A. 1992. Thrombin hydrolysis of an N-terminal peptide from fibrinogen Lille: kinetic and NMR studies. Biochemistry, 31: 4426-4431.